个人简介

教育背景 1994/9 - 1999/7，哈尔滨医科大学，临床医学，学士 1999/9 - 2002/7，哈尔滨医科大学，病理生理学，硕士 2002/9 - 2005/7，中国协和医科大学，药理学，博士 工作经历 2005/8 - 2008/5 北京奥维腾隆生物科技有限公司 项目经理 2008/10 - 2013/10 美国约翰霍普金斯大学医学院神经科学系、离子通道中心，博士后 2014/3 - 至今 中国医学科学院药物研究所，研究员，课题组长

研究领域

主要围绕疾病相关的离子通道，建立离子通道药物研发平台，发现新颖离子通道药物以及开展小分子调控机制研究。

1. 探索离子通道在神经系统疾病发生中的作用 2. 以离子通道为靶点的新药发现研究 3. 药物的心脏离子通道安全性评价研究

近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Wu, Y#., Zou, B#., Liang, L., Li, M., Tao, Y.-X., Yu, H*., Wang, X*., Li, M*., Loperamide inhibits sodium channels to alleviate inflammatory hyperalgesia, Neuropharmacology. 2017, 117: 282-291. (#,co-first authors) 2. Yu HB*, Li M, Wang WP, Wang XL*. High throughput screening technologies for ion channels. Acta Pharmacol Sin. 2016,37(1):34-43. 3. Yu HB*, Zou BY*, Wang XL, Li M. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay. Acta Pharmacol Sin. 2016,37(1):111-23. 4. Yu, H*, Zou, B., Wang, X., Li, M.. Effect of Tyrphostin AG879 on Kv4.2 and Kv4.3 potassium channels. Brit J Pharmacol. 2015, 172(13):3370-82 5. Peters CJ, Yu H, Tien J, Jan YN, Li M, Jan LY*. Four basic residues critical for the ion selectivity and pore blocker sensitivity of TMEM16A calcium-activated chloride channels. Proc Natl Acad Sci U S A. 2015 112(11):3547-52. 6. Du F, Babcock JJ, Yu H, Zou B, Li M*. Global analysis reveals families of chemical motifs enriched for HERG inhibitors. PLoS One. 2015, 10(2):e0118324. 7. Yu, H., Lin, Z., Mattmann, M., Zou, B., Terrenoire.C., Zhang, H., Wu, M., McManus, O. B., Kass, R. S., Lindsley, C. W., Hopkins, C. R.*, and Li, M*. Dynamic Subunit Stoichiometry Confers a Progressive Continuum of Pharmacological Sensitivity by KCNQ Channels. Proc Natl Acad Sci U S A 110, 2013,8732-8737. 8. Zhou, P., Yu, H., Gu, M., Nan, F., Gao, Z*, and Li, M*. PIP2 alters pharmacological selectivity for epilepsy-causing KCNQ channels. Proc Natl Acad Sci U S A 110, 8726-8731, 2013. 9. Zhang, H.#, Zou, B. #, Yu, H. #, Moretti, A., Wang, X., Yan, W., Babcock, J. J., Bellin, M., McManus, O. B., Tomaselli, G., Nan, F., Laugwitz, K. L., and Li, M*. Modulation of hERG potassium channel gating normalizes action potential duration prolonged by dysfunctional KCNQ1 potassium channel. Proc Natl Acad Sci U S A 2012,109, 11866-11871. (# Cofirst author) 10. Yu, H., Wu, M., Townsend, S. D., Zou, B., Long, S., Daniels, J. S., McManus, O. B., Li, M*, Lindsley, C. W., and Hopkins, C. R*. Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. ACS chem neurosci 2011, 2, 572-577. 11. Cheung, Y. Y., Yu, H., Xu, K., Zou, B., Wu, M., McManus, O. B., Li, M.*, Lindsley, C. W., and Hopkins, C. R*. Discovery of a series of 2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as novel molecular switches that modulate modes of K(v)7.2 (KCNQ2) channel pharmacology: identification of (S)-2-phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a potent, brain penetrant K(v)7.2 channel inhibitor. J Med Chem 2012, 55, 6975-6979. 12. Mattmann, M. E., Yu, H., Lin, Z., Xu, K., Huang, X., Long, S., Wu, M., McManus, O. B., Engers, D. W., Le, U. M., Li, M.*, Lindsley, C. W., and Hopkins, C. R*. Identification of (R)-N-(4-(4-methoxyphenyl)thiazol-2-yl)-1-tosylpiperidine-2-carboxamide, ML277, as a novel, potent and selective K(v)7.1 (KCNQ1) potassium channel activator. Bioorg Med Chem Lett 2012, 22, 5936-5941. 13. Du, F., Yu, H., Zou, B., Babcock, J., Long, S., and Li, M*. hERGCentral: a large database to store, retrieve, and analyze compound-human Ether-a-go-go related gene channel interactions to facilitate cardiotoxicity assessment in drug development. Assay Drug Dev Technol 2011, 9, 580-588. 14. Wang, H. R. #, Wu, M. #, Yu, H., Long, S., Stevens, A., Engers, D. W., Sackin, H., Daniels, J. S., Dawson, E. S., Hopkins, C. R., Lindsley, C. W.*, Li, M.*, and McManus, O. B. Selective inhibition of the K(ir)2 family of inward rectifier potassium channels by a small molecule probe: the discovery, SAR, and pharmacological characterization of ML133. ACS Chem Biol 2011, 6, 845-856. 15. Zou, B., Yu, H., Babcock, J. J., Chanda, P., Bader, J. S., McManus, O. B., and Li, M*. Profiling diverse compounds by flux- and electrophysiology-based primary screens for inhibition of human Ether-a-go-go related gene potassium channels. Assay Drug Dev Technol 2010, 8, 743-754. 16. Yu, HB, Li, ZB, Zhang, HX., and Wang, XL*. Role of potassium channels in Abeta(1-40)-activated apoptotic pathway in cultured cortical neurons. J Neurosci Res 2006, 84, 1475-1484.